Oncology Central

Tecentriq combo delivers survival benefit to NSCLC patients

A Phase III study by Genentech has met its co-primary endpoint of overall survival at interim analysis and demonstrated that first-line treatment with the combination of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced non-squamous non-small cell lung cancer live significantly longer compared with Avastin plus carboplatin and paclitaxel.
To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.